Elixiron Immunotherapeutics

Elixiron Immunotherapeutics is driven by an international team with a shared vision to produce next-generation immunotherapies. This vision drives our mission to target rare and inflammatory disorders as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.

Elixiron Immunotherapeutics headquartered in Asia, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $237.4M in funding across 16 round(s). With a team of 11-50 employees, Elixiron Immunotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - Elixiron Immunotherapeutics, raised $1.0M. Discover more about their projects, partnerships, and impact on our platform.